Ablynx NV suffered the slings and arrows of outrageous fortune in 2011 as it achieved clinical proof of concept for the first time for one of its platform products, only to find subsequently that the programme was being returned to it by its partner, Pfizer Inc. The US company cited a change in its strategic priorities.
